BB Biotech (BION.SW) Osake Kurssi
BB Biotech Kurssi
BB Biotechn liikevaihto on supistunut 7,2 % vuodessa viimeisten 19 vuoden aikana 76,81 M CHF:een. Osakekohtainen tulos on kasvanut 7,8 % vuodessa viimeisten 19 vuoden aikana. BB Biotechn nettomarginaali on nyt 752,7 %, noussut 102,2 %:sta muutama vuosi sitten. BB Biotechn osinkotuotto on tällä hetkellä noin 7,74 %. Jakosuhde on noin 17 % tuloksesta. Osinko on kasvanut 11,6 % vuodessa viimeisten 15 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 58,87 CHF, eli yli nykyhintaa 18,9 %. 10 analyytikosta 9 suosittaa ostoa — kokonaiskonsensus on Osta.
BB Biotech osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
BB Biotech liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset BB Biotech -osakkeesta
BB Biotech AG is a biotechnology investment company headquartered in Switzerland. The company primarily focuses on investing in a portfolio of innovative and promising biotechnology companies, with a particular emphasis on companies developing and commercializing breakthrough therapies. BB Biotech AG aims to support and generate long-term value by investing in cutting-edge biotech companies that address unmet medical needs and have strong growth potential. By leveraging their extensive expertise and network within the biotech industry, BB Biotech AG aims to provide investors with an attractive investment opportunity in the rapidly evolving field of biotechnology.
BB Biotech AG is primarily active in the biotechnology industry.
Some of the main competitors of BB Biotech AG in the market include Roche Holding AG, Novartis AG, and Johnson & Johnson.
BB Biotech AG is a renowned Swiss investment company specializing in the healthcare sector. Established in 1993, BB Biotech has a rich history of success in generating long-term value for its shareholders. The company primarily focuses on investing in innovative biotech companies that exhibit strong growth potential. BB Biotech benefits from an experienced team of professionals dedicated to thoroughly assessing and selecting promising investment opportunities within the biotech industry. With its extensive expertise and broad network, BB Biotech seeks to capitalize on cutting-edge advancements in the healthcare sector. Throughout its history, BB Biotech has consistently delivered impressive returns for investors, solidifying its position as a leading player in the biotech investment space.
BB Biotech AG has achieved significant milestones in its history. Some notable achievements include the successful launch of its investment strategy focused on globally listed biotech companies. The company has also been able to deliver consistent returns to its shareholders, with a strong track record of portfolio performance. BB Biotech AG has established itself as a leader in the biotech sector, with a well-diversified portfolio of investments in innovative companies. The company has also been actively involved in supporting the development of breakthrough therapies and advancements in the biotech industry. Overall, BB Biotech AG's achievements reflect its commitment to supporting the growth and success of the biotech sector.
BB Biotech AG is primarily present in Switzerland and Germany.
BB Biotech AG represents strong values and a solid corporate philosophy. As a leading biotech investment company, BB Biotech AG focuses on long-term capital appreciation through investments in the biotechnology industry. They strive to support innovative companies that develop cutting-edge therapies and healthcare solutions. This strategy aligns with their commitment to drive advancements and improvements in the healthcare sector. By investing in emerging biotech companies with significant growth potential, BB Biotech AG aims to generate sustainable returns for its shareholders.
Analyytikot asettavat tällä hetkellä BB Biotech-osakkeelle keskimääräisen tavoitehinnan 58,28 CHF (mediaani: 58,87 CHF), mikä merkitsee +17,7 % viimeisimpään hintaan verrattuna. Konsensus perustuu 10 analyytikkoarvioon.
10 analyytikkoa arvioi tällä hetkellä BB Biotech-osaketta: 9 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat BB Biotech-yhtiöltä 1,28 Mrd. CHF liikevaihtoa ja 2,57 CHF osakekohtaista tulosta.
Nykyisellä valuuttakurssilla BB Biotech-osake noteerataan hintaan 53,42 EUR (49,50 CHF).
BB Biotech-osake (BION.SW) on listattuna 6 pörssissä, muun muassa: London (0JYO.L), SIX (Zürich) (BION.SW), XETRA (BBZA.DE), München (BBZA.MU), Düsseldorf (BBZA.DU), Hamburg (BBZA.HM).
BB Biotech AG is a Swiss investment company specializing in biotechnology. The company actively invests worldwide in biotechnology companies working on innovative therapies to combat various diseases. Their approach focuses on companies developing medications and therapies based on genomic and protein research. The business model of BB Biotech AG is based on their position as strong and experienced investors in the biotechnology field. They invest in a variety of companies within their portfolio that focus on the development of innovative therapeutic options. The company strives for long-term success by investing in companies that utilize innovative technologies for drug manufacturing. BB Biotech AG is a key player in the global biotech market and a significant investor in this sector. In addition to their investment strategy, BB Biotech AG also offers comprehensive consulting services and expertise in the biotechnology and life sciences field. The company supports biotechnology companies in various stages of development, from research and development to drug approval and marketing. Their portfolio includes companies from various areas of biotechnology and life sciences, including biopharmaceuticals, diagnostics, medical technology, and genomics. Some of the key companies in their portfolio are Biotechnology Innovation Organization, Regeneron Pharmaceuticals, Gilead Sciences, Vertex Pharmaceuticals, and Blueprint Medicines. The company aims to actively manage and optimize their portfolio to provide investors with the highest benefit. Through careful research, analysis, and monitoring of biotechnology markets worldwide, BB Biotech AG is able to identify opportunities and act in a timely manner. Overall, BB Biotech AG offers an innovative business model based on a deep understanding of the biotechnology industry and a comprehensive portfolio of companies utilizing innovative technologies for drug manufacturing. The company provides comprehensive investment and consulting services and is a major player in the global biotech market.
odotettu liikevaihto BB Biotech on 1,28 Mrd. CHF. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto BB Biotech on 141,47 M CHF. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
BB Biotech:n hinta-voitto-suhde (P/E) on tällä hetkellä 19,30. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan BB Biotech-osakkeen arvostusta.
BB Biotech:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,13. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii BB Biotech-osakkeen arvostuskennuslukuna.
BB Biotech:n Eulpool-laatuscore on 4/10.
BB Biotech:n ISIN on CH0038389992. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
BB Biotech:n WKN on A0NFN3. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
BB Biotech:n ticker on BION.SW. Tämä pörssinoteeraus käytetään BB Biotech-osakkeiden kauppaan pörssissä.
BB Biotech osake
BB Biotech vertaisryhmä
BB Biotech Ticker
BB Biotech FIGI
Kaikki tunnusluvut ja syvällinen analyysi BB Biotech:sta
Meidän osakeanalyysimme BB Biotech-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut BB Biotech:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: